David van Avermaete

Roche Diagnostics Corp. develops and manufactures diagnostic products. It offers anticoagulation management, blood gas and electrolytes, cholesterol and urinalysis products. The firm provides a broad portfolio of tools that help healthcare providers in the prevention, diagnosis and management of diseases like HPV, HIV, heart failure and diabetes, as well as other medical conditions, such as fertility and blood coagulation. Its products and services uses by researchers, physicians, patients, hospitals and laboratories worldwide. The company was founded in 1964 by Willard Eason and is headquartered in Indianapolis, IN.

Lifescan, Inc. engages in the development, manufacture, and market of blood glucose monitoring products. Its portfolio includes personal blood glucose meters, testing strips, lancets, point of care testing systems and integrated digital solutions. The company was founded by Gary H. Stroy in 1981 and is headquartered in Wayne, PA.

VeraLight, Inc. develops noninvasive technologies for the disease detection and health monitoring of diabetes epidemics. It offers a noninvasive diabetes screening system designed to provide a method for screening pre-diabetes based on the presence of diabetes-related biomarkers found in skin. The company was founded by David Van Avermaete and John Maynard in October 2004 and is headquartered in Albuquerque, NM.

InLight Solutions, Inc. researches, develops and engineers sensor-based measurement systems for life science applications. Its products include Critical care, Noninvasive Glucose, Bioreator Monitoring and Custom Applications. The firm commercializes product applications with their development partners. The company was founded by William A. Miller in 1993 and is headquartered in Albuquerque, NM.

Biotope Plus Ltd, founded in 2007, specializes in biological sewage purification. The company, headed by scientists and engineers with years of experience in the aforementioned field, has developed a unique method for purifying sewage. The company focuses on domestic and urban sewage needs, of populations from 500 up to 30,000 individuals. Its devices are suitable for remote settlements as well as towns, new neighborhoods, army and government facilities. They upgrade existing wastewater treatment plants for a complete biological tertiary treatment level and reducing excessive sludge quantity. Its products are also suitable for the industrial and agricultural markets. The company set up its first prototype bioreactor in the southern part of Israel (The Negev). The reactor is fully operational and is designed for purifying up to 150 m³/day of domestic wastewater.